What is Phil?
Phil operates as a modern alternative to traditional pharmaceutical access, affordability, and distribution models. By integrating digital stakeholder experiences, patient access services, market access tools, and flexible distribution strategies, the company empowers pharmaceutical manufacturers to ensure timely and affordable therapy access for patients. This comprehensive approach addresses critical pain points in the healthcare supply chain, leveraging technology to enhance efficiency and patient outcomes.
How much funding has Phil raised?
Phil has raised a total of $176.1M across 6 funding rounds:
Other Financing Round
$2.1M
Series A
$10M
Series B
$25M
Series C
$23M
Series D
$56M
Debt
$60M
Other Financing Round (2015): $2.1M with participation from Forerunner Ventures, FJ Labs, Fabrice Grinda, Eniac Ventures, Uncork Capital, and Tom Williams
Series A (2017): $10M led by Forerunner Ventures, Transmedia Capital, Silicon Valley Bank, Eniac Ventures, Softtech VC, Uncork Capital, and Crosslink Capital
Series B (2019): $25M supported by Uncork Capital, Crosslink Capital, GreatPoint Energy, and Tarsadia Hotels
Series C (2021): $23M, investors not publicly disclosed
Series D (2021): $56M backed by Warburg Pincus
Debt (2025): $60M with participation from K2 HealthVentures
Key Investors in Phil
Uncork Capital
Uncork Capital is a seed-stage venture firm that commits early to startups and remains involved to provide critical support. The firm focuses on assisting companies through the challenges of early growth, aiming to build lasting partnerships.
Crosslink Capital
Crosslink Capital is an investment firm that partners with ambitious early-stage founders to build category-defining companies. With a focus on seed and Series A investments, the firm has a diverse portfolio across North America, boasting over 50 exits including 17 IPOs.
Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm renowned for its expertise in growth investing. Operating as a private partnership, the firm leverages decades of experience to support investors and management teams in building long-term, sustainable success across diverse market cycles.
What's next for Phil?
The substantial enterprise-level funding and recent strategic investment signal Phil's readiness for accelerated scaling and market expansion. With a robust foundation in technology-driven solutions for pharmaceutical distribution and patient access, the company is well-positioned to further innovate and solidify its market leadership. Future strategic initiatives are likely to focus on enhancing its digital platform, expanding its network of pharmaceutical partners, and deepening its impact on patient affordability and timely therapy delivery. The consistent backing from notable investors suggests a clear path toward achieving significant milestones in the healthcare technology sector.
See full Phil company page
